Heidelberg Pharma AG

XTRA:HPHA Stock Report

Market Cap: €103.5m

Heidelberg Pharma Future Growth

Future criteria checks 1/6

Heidelberg Pharma's earnings are forecast to decline at 33% per annum while its annual revenue is expected to grow at 16.6% per year. EPS is expected to decline by 33% per annum.

Key information

-33.0%

Earnings growth rate

-33.0%

EPS growth rate

Biotechs earnings growth42.2%
Revenue growth rate16.6%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Oct 2024

Recent future growth updates

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21
Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Oct 16
Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Nov 28
Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Mar 27
Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Mar 15
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17
Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Earnings and Revenue Growth Forecasts

XTRA:HPHA - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
11/30/202613-39N/AN/A1
11/30/202512-46N/AN/A2
11/30/202411-22N/AN/A2
8/31/20248-19-30-30N/A
5/31/202410-13-33-32N/A
2/29/20249-18-34-34N/A
11/30/202310-20-35-34N/A
8/31/20239-22-35-34N/A
5/31/202311-27-35-34N/A
2/28/202320-19-14-13N/A
11/30/202219-20-9-9N/A
8/31/202217-21-9-8N/A
5/31/202213-22-7-6N/A
2/28/20222-27-28-27N/A
11/30/20212-26-28-27N/A
8/31/20212-25-25-23N/A
5/31/20217-22-24-23N/A
2/28/20217-20-21-20N/A
11/30/20209-18-19-18N/A
8/31/202010-17-18-17N/A
5/31/20207-15-12-11N/A
2/29/20208-12-11-10N/A
11/30/20197-10-10-9N/A
8/31/20197-10-10-9N/A
5/31/20196-11-12-12N/A
2/28/20194-12-11-10N/A
11/30/20184-12-11-10N/A
8/31/20184-11-11-10N/A
5/31/20183-11N/A-8N/A
2/28/20182-11N/A-9N/A
11/30/20172-11N/A-8N/A
8/31/20172-10N/A-7N/A
5/31/20172-8N/A-8N/A
2/28/20172-7N/A-7N/A
11/30/20162-6N/A-7N/A
8/31/20162-7N/A-6N/A
5/31/20162-7N/A-5N/A
2/29/20162-7N/A-5N/A
11/30/20153-7N/A-5N/A
8/31/20153-5N/A-4N/A
5/31/20155-3N/A-3N/A
2/28/20154-4N/A-4N/A
11/30/20144-6N/A-7N/A
8/31/20147-5N/A-7N/A
5/31/20149-6N/A-10N/A
2/28/201411-6N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HPHA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HPHA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HPHA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HPHA's revenue (16.6% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: HPHA's revenue (16.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HPHA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 13:10
End of Day Share Price 2024/12/27 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heidelberg Pharma AG is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruno BulicBaader Helvea Equity Research
Christian WeizBaader Helvea Equity Research
Gregory RamirezBryan Garnier & Co